

November 11, 2021
SymBio Pharmaceuticals Limited
(Securities Code: 4582)
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year Ending December 31, 2021

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, Japan, "SymBio" or the "Company") today announced its financial results for the third quarter of the fiscal year ending December 31, 2021. SymBio has achieved operating profit for two consecutive quarters in the second and third quarters of the current fiscal year.

Highlights of Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2021

In the third quarter of the fiscal year, the Company made gradual progress in remediating effects of treatment delays due to countermeasures against COVID-19, such as vaccination of elderly patients. In addition, the approval of BR therapy and P-BR therapy for relapsed or refractory diffuse large B-cell lymphoma ("r/r DLBCL") on March 23, 2021 and the NHI drug price listing of polatuzumab vedotin by Chugai Pharmaceutical Co. Ltd. on March 19, 2021 contributed to the increase in sales. As a result, net sales for the third quarter increased by 680 million yen from the second quarter to 2,406 million yen, and operating income increased by 603 million yen from the second quarter to 619 million yen.

In the first nine months of the current fiscal year, net sales were 5,553 million yen and operating income was 424 million yen.

Progress of major milestones since the announcement of the second quarter results

First Patient Dosed in Phase II clinical trial for BCV IV

On August 16, 2021 (Pacific Daylight Time in USA), we achieved First Patient Dosed in the global Phase II clinical trial of an intravenous formulation of the anti-viral drug brincidofovir (BCV IV) for treatment of pediatric adenovirus infection.

Related press release: https://www.symbiopharma.com/news_e/20210817e.pdf

Initiation of controls on shipment of TREAKISYM® FD Formulation

On September 21, 2021, due to delays in conversion from TREAKISYM® freeze-dry lyophilized injection formulation ("FD") to ready-to-dilute liquid formulation ("RTD") and the possibility of a supply shortage of FD, the Company initiated controls on shipments of FD. However, with the understanding and cooperation of health care professionals, the conversion to RTD formulation has progressed rapidly.

Related press release: https://www.symbiopharma.com/news_e/20210921e.pdf


Symbio Pharma USA, Inc. begins Operations

On October 11, 2021 (Pacific Daylight Time in USA), Dr. Carolyn Yanavich was appointed as the Vice President, and Head of Project Management and Clinical Operations of Symbio Pharma USA, Inc. (“Symbio Pharma USA”), the Company’s wholly-owned U.S. subsidiary. This appointment will enable Symbio Pharma USA to begin operations and is expected to further accelerate the global business development of BCV IV. It is a significant step in the Company’s transformation into a global specialty pharmaceutical company.

Related press release: https://www.symbiopharma.com/news_e/20211012e.pdf

Message from Dr. Carolyn Janavich: https://www.symbiopharma.com/vision_e/09.html

Quarterly and Cumulative Results for the Fiscal Year Ended December 31, 2021



[Contact]

Investor Relations

Tel: +81(0)3 5472 1125